Merck receives 2016 ENERGY STAR Sustained Excellence Award From US Environmental Protection Agency
Company receives EPA honor for 11th consecutive year.
Merck (MSD) has received an ENERGY STAR 2016 Partner of the Year — Sustained Excellence Award from the US Environmental Protection Agency (EPA) for its continued improvement of energy performance and leadership in energy management in both the pharmaceutical and industrial sectors.
Merck has been an ENERGY STAR partner since 1995 and recognized by the EPA for 11 consecutive years, two times as Partner of the Year and now a ninth time for Sustained Excellence.
“Merck is proud of our partnership with ENERGY STAR, because it helps us promote our energy program and provides guidance to use energy more efficiently,” said Don Watson, vice president, Global Workplace & Enterprise Services, Merck. “We are committed to the efficient use of our natural resources and reducing the environmental impact of our operations.”
The award recognizes one Merck manufacturing site that has achieved ENERGY STAR rankings in the top 25% of pharmaceutical plant energy performance nationwide: Las Piedras, Puerto Rico.
Also achieving certification this year were office buildings in Cokesbury and Branchburg, NJ, as well as an office building in Upper Gwynedd, Pa.
“By continued collaboration with ENERGY STAR, Merck is helping Americans save money, save energy, and do their part to reduce our nation’s greenhouse gas emissions that exacerbate climate change,” said EPA Administrator Gina McCarthy. “I’m proud to recognize Merck with the highest form of ENERGY STAR recognition, as the winner of the 2016 Partner of the Year — Sustained Excellence Award. Merck demonstrates a strong commitment to energy efficiency and to preserving a healthy planet for future generations.”
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.